Bagal, Sharan K. et al. published their research in Journal of Medicinal Chemistry in 2018 | CAS: 25676-75-9

4-Bromo-1-methylimidazole (cas: 25676-75-9) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Quality Control of 4-Bromo-1-methylimidazole

Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain was written by Bagal, Sharan K.;Andrews, Mark;Bechle, Bruce M.;Bian, Jianwei;Bilsland, James;Blakemore, David C.;Braganza, John F.;Bungay, Peter J.;Corbett, Matthew S.;Cronin, Ciaran N.;Cui, Jingrong Jean;Dias, Rebecca;Flanagan, Neil J.;Greasley, Samantha E.;Grimley, Rachel;James, Kim;Johnson, Eric;Kitching, Linda;Kraus, Michelle L.;McAlpine, Indrawan;Nagata, Asako;Ninkovic, Sacha;Omoto, Kiyoyuki;Scales, Stephanie;Skerratt, Sarah E.;Sun, Jianmin;Tran-Dube, Michelle;Waldron, Gareth J.;Wang, Fen;Warmus, Joseph S.. And the article was included in Journal of Medicinal Chemistry in 2018.Quality Control of 4-Bromo-1-methylimidazole This article mentions the following:

Hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4) are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, TrkC). Moreover, inhibition of the TrkA kinase pathway in pain has been clin. validated by the NGF antibody tanezumab leading to significant interest in the development of small mol. inhibitors of TrkA. Furthermore, Trk inhibitors having an acceptable safety profile will require minimal brain availability. Herein we discuss the discovery of two potent, selective, peripherally restricted, efficacious and well-tolerated series of pan-Trk inhibitors which successfully delivered three candidate quality compounds I, II and III. All three compounds are predicted to possess low metabolic clearance in human that does not proceed via aldehyde oxidase-catalyzed reactions, thus addressing the potential clearance prediction liability associated with our current pan-Trk development candidate PF-06273340. In the experiment, the researchers used many compounds, for example, 4-Bromo-1-methylimidazole (cas: 25676-75-9Quality Control of 4-Bromo-1-methylimidazole).

4-Bromo-1-methylimidazole (cas: 25676-75-9) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Quality Control of 4-Bromo-1-methylimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem